Investors in SPDR Series Trust - S&P Biotech ETF (Symbol: XBI) saw new options begin trading today, for the May 2nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

Although LFSC launched just five months ago, the team at Emerald Advisers is highly experienced. Read why I don't recommend ...

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund launched on 01/31/2006.

Shares in financial firm Stifel (SF) dropped 3% today after it was told to cough up $132.5 million in damages to a U.S.

Short interest in SPDR Series Trust SPDR S&P Biotech ETF (ARCA:XBI) decreased during the last reporting period, falling from 58.01M to 56.14M. This put -% of the company's publicly available ...

SPDR S&P Biotech ETF Stock Down 1.3 % XBI stock opened at $87.10 on Friday. The company has a 50-day simple moving average of $91.06 and a 200 day simple moving average of $95.80. The company has ...

The SPDR S&P Dividend ETF offers a hybrid strategy split between high dividend yield and dividend growth stocks.

SPDR ® S&P Biotech ETF earns an Average Process Pillar rating. Morningstar's algorithmically assigned Passive Process ratings are first formulated by comparing the historical efficacy of passive ...

The SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market. The ETF industry has ...

A summary for the SPDR S&P Biotech ETF technical analysis data. Live signals range from strong buy, buy, neutral, sell to strong sell. Assess XBI's detailed technical analysis based on the buy/sell ...